Combining psychological therapy with ketamine treatments resulted in longer periods of abstinence for those with severe alcohol use disorder, a new study reports.
Study demonstrates the safety and feasibility of psilocybin for the treatment of mental health disorders.
Researchers have identified a novel biomarker for depression and antidepressant response. The biomarker can be identified and monitored through blood samples.
Study reveals there is no evidence a six-month course of vitamin D supplementation improves mental or physical health for those with psychosis. However, while vitamin D supplementation did not improve symptoms, 77% of patients experienced vitamin D deficiencies.
Ketamine reduces symptoms of depression and suicidal thoughts within four hours of a single treatment, and the effects last for up to two weeks. Additional treatments may prolong the effects, researchers say.
Hippocampal HCN channels are more highly expressed in people with major depressive disorder. Antidepressants that increase cAMP signaling interfere with TRIP8b's ability to bind to HCN channels, helping to restore cognitive ability in those with MDD.
People with untreated depression have lower levels of mitochondrial proteins. For those who responded to the SSRI antidepressants, the proteins returned to a normal level, but showed no increase in those who did not respond to medication.
A growing body of evidence suggests psychedelics including psilocybin and LSD show promise in providing lasting relief from symptoms for those suffering some mental health disorders. Researchers found DOI, a similar drug to LSD, reduced negative behavioral responses following fear triggers in mouse models of anxiety.
Ketamine's rapid antidepressant action is due to specific synaptic effects, researchers report.
Combining neuroimaging and artificial intelligence, researchers identified novel brain signatures unique to the response of each antidepressant.